Notably, the selective inhibition of HMGB1 has been shown to exert chondroprotective effects by blocking IL1-induced MMP expression, emphasizing a feasible therapeutic target for TMD [77]. This evidence concerns the gene IL1B and temporomandibular joint disorder.